Rhythm Pharmaceuticals Inc. Insider Trading

RYTM

Last 12 months

Insiders sold $38.6M and bought nothing on the open market.

98% of the selling was scheduled in advance under 10b5-1 plans. Corporate Controller & CAO Christopher Paul German sold 503K on Mar 4, 97% of their stake, outside a plan. The last open-market buy by an executive or director was in Mar 2021.

Net open-market

−$38.6M

0 buys · 15 sales

Under a 10b5-1 plan

98%

of the value sold

Insiders who bought / sold

0 / 9

executives and directors

Last open-market buy

Mar 2021

Mar 30, 2021

Get an email when RYTM's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Sep 14	David P Meeker President and CEO	Sold10b5-1 plan 5 parts	50,000	$102.67 average	$5.13M	17%	Form 4
Aug 31	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 3 parts	62,774	$105.46 average	$6.62M	36%	Form 4
Aug 13	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan	5,079	$119.75	608K	24%	Form 4
Aug 13	Alastair Garfield Chief Scientific Officer	Sold10b5-1 plan 4 parts	7,763	$117.57 average	913K	77%	Form 4
Aug 13	Jennifer Kayden Lee EVP, Head of North America	Sold10b5-1 plan	75,834	$117.38	$8.9M	100%	Form 4
Aug 12	Yann Mazabraud EVP, Head of International	Sold10b5-1 plan 6 parts	57,000	$116.15 average	$6.62M	51%	Form 4
Jun 22	Lynn A. Tetrault Director	Sold10b5-1 plan	37,000	$100.32	$3.71M	84%	Form 4
May 15	Christopher Paul German Corporate Controller & CAO	SoldNo plan	4,643	$92.21	428K	100%	Form 4
Mar 4	Christopher Paul German Corporate Controller & CAO	SoldNo plan	5,614	$89.56	503K	97%	Form 4
Feb 17 – 19	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 9 parts	7,954	$101.31 average	806K	6.7%	Form 4
Feb 10 – 12	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 10 parts	7,071	$100.21 average	709K	5.6%	Form 4
Feb 4 – 5	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 4 parts	6,628	$106.02 average	703K	5.0%	Form 4
Dec 11, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan	3,350	$111.00	372K	14%	Form 4
Nov 20, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan	3,350	$105.00	352K	14%	Form 4
Nov 7, 2025 – Nov 10, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan 2 parts	22,866	$99.00 average	$2.26M	52%	Form 4
Oct 30, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan	9,748	$115.24	$1.12M	53%	Form 4
Oct 28, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan	2,815	$115.01	324K	25%	Form 4
Oct 16, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan 3 parts	14,437	$112.03 average	$1.62M	63%	Form 4
Sep 2, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan	16,781	$105.30	$1.77M	66%	Form 4
Aug 21, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan	4,188	$100.07	419K	33%	Form 4
Aug 12, 2025 – Aug 13, 2025	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 2 parts	28,088	$96.29 average	$2.7M	19%	Form 4
Aug 12, 2025	Christopher Paul German Corporate Controller & CAO	Sold10b5-1 plan	1,500	$95.00	143K	62%	Form 4
Aug 11, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan	3,984	$90.08	359K	32%	Form 4
Jul 29, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan	1,520	$85.93	131K	6.8%	Form 4
Jul 9, 2025	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 3 parts	42,120	$80.48 average	$3.39M	26%	Form 4
Jul 9, 2025	Joseph Shulman Chief Technical Officer	Sold10b5-1 plan 2 parts	7,969	$77.78 average	620K	48%	Form 4
Jul 9, 2025	Christopher Paul German Corporate Controller & CAO	Sold10b5-1 plan 2 parts	3,817	$80.75 average	308K	81%	Form 4
Jul 9, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan 3 parts	15,572	$77.13 average	$1.2M	45%	Form 4
Jul 2, 2025	Alastair Garfield Chief Scientific Officer	Sold10b5-1 plan 2 parts	1,319	$64.81 average	85K	30%	Form 4
Jun 10, 2025	Christopher Paul German Corporate Controller & CAO	Sold10b5-1 plan	2,069	$67.19	139K	52%	Form 4
Jun 6, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan	7,031	$68.05	478K	27%	Form 4
Jun 3, 2025	David W J McGirr Director	Sold10b5-1 plan 2 parts	65,431	$65.22 average	$4.27M	96%	Form 4
Jun 3, 2025	David P Meeker President and CEO	Sold10b5-1 plan 2 parts	43,620	$65.04 average	$2.84M	18%	Form 4
May 30, 2025	Hunter C Smith Chief Financial Officer	Sold10b5-1 plan 2 parts	23,400	$61.41 average	$1.44M	18%	Form 4
Apr 29, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan	7,031	$65.09	458K	27%	Form 4
Apr 29, 2025	Yann Mazabraud EVP, Head of International	Sold10b5-1 plan	6,745	$65.08	439K	15%	Form 4
Apr 8, 2025	Pamela J. Cramer Chief Human Resources Officer	Sold10b5-1 plan 4 parts	20,760	$60.14 average	$1.25M	52%	Form 4
Apr 8, 2025	Yann Mazabraud EVP, Head of International	Sold10b5-1 plan 2 parts	17,750	$60.98 average	$1.08M	44%	Form 4
Mar 21, 2025	Christopher Paul German Corporate Controller & CAO	Sold10b5-1 plan	344	$54.23	19K	11%	Form 4
Mar 14, 2025	Yann Mazabraud EVP, Head of International	Sold10b5-1 plan 2 parts	75,000	$51.48 average	$3.86M	65%	Form 4

Sep 1410b5-1 plan
David P Meeker
President and CEO · sold 50,000 at avg $102.67
$5.13M
17% of stake
Aug 3110b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 62,774 at avg $105.46
$6.62M
36% of stake
Aug 1310b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 5,079 at $119.75
608K
24% of stake
Aug 1310b5-1 plan
Alastair Garfield
Chief Scientific Officer · sold 7,763 at avg $117.57
913K
77% of stake
Aug 1310b5-1 plan
Jennifer Kayden Lee
EVP, Head of North America · sold 75,834 at $117.38
$8.9M
100% of stake
Aug 1210b5-1 plan
Yann Mazabraud
EVP, Head of International · sold 57,000 at avg $116.15
$6.62M
51% of stake
Jun 2210b5-1 plan
Lynn A. Tetrault
Director · sold 37,000 at $100.32
$3.71M
84% of stake
May 15No plan
Christopher Paul German
Corporate Controller & CAO · sold 4,643 at $92.21
428K
100% of stake
Mar 4No plan
Christopher Paul German
Corporate Controller & CAO · sold 5,614 at $89.56
503K
97% of stake
Feb 17 – 1910b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 7,954 at avg $101.31
806K
6.7% of stake
Feb 10 – 1210b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 7,071 at avg $100.21
709K
5.6% of stake
Feb 4 – 510b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 6,628 at avg $106.02
703K
5.0% of stake
Dec 11, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 3,350 at $111.00
372K
14% of stake
Nov 20, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 3,350 at $105.00
352K
14% of stake
Nov 7, 2025 – Nov 10, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 22,866 at avg $99.00
$2.26M
52% of stake
Oct 30, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 9,748 at $115.24
$1.12M
53% of stake
Oct 28, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 2,815 at $115.01
324K
25% of stake
Oct 16, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 14,437 at avg $112.03
$1.62M
63% of stake
Sep 2, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 16,781 at $105.30
$1.77M
66% of stake
Aug 21, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 4,188 at $100.07
419K
33% of stake
Aug 12, 2025 – Aug 13, 202510b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 28,088 at avg $96.29
$2.7M
19% of stake
Aug 12, 202510b5-1 plan
Christopher Paul German
Corporate Controller & CAO · sold 1,500 at $95.00
143K
62% of stake
Aug 11, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 3,984 at $90.08
359K
32% of stake
Jul 29, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 1,520 at $85.93
131K
6.8% of stake
Jul 9, 202510b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 42,120 at avg $80.48
$3.39M
26% of stake
Jul 9, 202510b5-1 plan
Joseph Shulman
Chief Technical Officer · sold 7,969 at avg $77.78
620K
48% of stake
Jul 9, 202510b5-1 plan
Christopher Paul German
Corporate Controller & CAO · sold 3,817 at avg $80.75
308K
81% of stake
Jul 9, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 15,572 at avg $77.13
$1.2M
45% of stake
Jul 2, 202510b5-1 plan
Alastair Garfield
Chief Scientific Officer · sold 1,319 at avg $64.81
85K
30% of stake
Jun 10, 202510b5-1 plan
Christopher Paul German
Corporate Controller & CAO · sold 2,069 at $67.19
139K
52% of stake
Jun 6, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 7,031 at $68.05
478K
27% of stake
Jun 3, 202510b5-1 plan
David W J McGirr
Director · sold 65,431 at avg $65.22
$4.27M
96% of stake
Jun 3, 202510b5-1 plan
David P Meeker
President and CEO · sold 43,620 at avg $65.04
$2.84M
18% of stake
May 30, 202510b5-1 plan
Hunter C Smith
Chief Financial Officer · sold 23,400 at avg $61.41
$1.44M
18% of stake
Apr 29, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 7,031 at $65.09
458K
27% of stake
Apr 29, 202510b5-1 plan
Yann Mazabraud
EVP, Head of International · sold 6,745 at $65.08
439K
15% of stake
Apr 8, 202510b5-1 plan
Pamela J. Cramer
Chief Human Resources Officer · sold 20,760 at avg $60.14
$1.25M
52% of stake
Apr 8, 202510b5-1 plan
Yann Mazabraud
EVP, Head of International · sold 17,750 at avg $60.98
$1.08M
44% of stake
Mar 21, 202510b5-1 plan
Christopher Paul German
Corporate Controller & CAO · sold 344 at $54.23
19K
11% of stake
Mar 14, 202510b5-1 plan
Yann Mazabraud
EVP, Head of International · sold 75,000 at avg $51.48
$3.86M
65% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch RYTM, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with RYTM

CompareIntrinsic value

PTGXProtagonist Therapeutics Inc.

$143.37+2.23%54

RIGLRigel Pharmaceuticals, Inc.

$51.29+4.97%87

HROWHarrow Inc.

$28.75+0.74%46

ARVNArvinas Inc.

$7.42+4.65%40

PHATPhathom Pharmaceuticals Inc.

$5.68-1.05%10

SNDXSyndax Pharmaceuticals Inc.

$10.45-26.87%0

SDGRSchrodinger, Inc.

$28.52+4.93%36

LGNDLigand Pharmaceuticals Inc.

$316.13+0.83%36

Held by ETFs

RYTM is in 68 US ETFs. The largest of them, with RYTM's weight in each:

Spot a number that looks wrong? Check it in RYTM's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing RYTM

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.